South Korea’s Ministry of Food and Drug Safety has decided to limit the usage of Hanmi Pharmaceutical Co. Ltd.'s EGFR inhibitor olmutinib only to patients who agree to use the drug after receiving thorough explanations from doctors on possible side effects including serious adverse skin reactions.
Olmutinib, which was approved in the country in May and launched for the first time globally in the country earlier...